Cytokinetics CYTK Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's unrealized gains (losses) on available-for-sale securities?
- Cytokinetics (CYTK) reported unrealized gains (losses) on available-for-sale securities of -$1.84M in Q1 2026.
- How has Cytokinetics's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Cytokinetics's unrealized gains (losses) on available-for-sale securities decreased by 239.7% year-over-year, from -$541K to -$1.84M.
- What does unrealized gains (losses) on available-for-sale securities mean?
- The change in value of investment securities that the company still holds.
- How do you interpret unrealized gains (losses) on available-for-sale securities?
- Positive values indicate market appreciation of investments, while negative values indicate market depreciation.
- How does unrealized gains (losses) on available-for-sale securities compare across companies?
- Common for companies holding significant cash equivalents or marketable securities in their treasury.